178 research outputs found
ΠΠΠΠ―ΠΠΠ ΠΠΠ ΠΠΠΠ’Π ΠΠ ΠΠΠ’ΠΠΠ¦ΠΠΠΠ Π‘ΠΠΠ©ΠΠΠΠ― Π ΠΠ ΠΠΠΠ’ΠΠ¦ΠΠ ΠΠΠΠΠΠΠΠ ΠΠ Π₯ΠΠ ΠΠΠ’ΠΠ ΠΠ‘Π’ΠΠΠ ΠΠ‘ΠΠΠΠΠΠΠΠΠ ΠΠΠΠ Π«Π’ΠΠ―: Π ΠΠΠ¬ Π ΠΠ‘ΠΠ«ΠΠΠΠΠ―
Π’Π΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΡΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² Π°ΡΠΎΠΌΠ½ΠΎΠ³ΠΎ ΡΠ°ΡΠΏΡΠ»Π΅Π½ΠΈΡ Π½Π° Π²Π΅Π»ΠΈΡΠΈΠ½Ρ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΉ ΠΈ ΡΠΊΠΎΡΠΎΡΡΡ ΡΠΎΡΡΠ°Β ΠΏΠΎΠΊΡΡΡΠΈΡ, ΠΏΠΎΠ»ΡΡΠ°Π΅ΠΌΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠ»Π°Π·ΠΌΠ΅Π½Π½ΠΎ-ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΠΌΠΏΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π° ΡΠΌΠ΅ΡΠ΅Π½ΠΈΡ Π½Π°Β ΠΏΠΎΠ΄Π»ΠΎΠΆΠΊΠ΅ ΠΈ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ³Π»Π°Ρ
ΠΏΠ°Π΄Π΅Π½ΠΈΡ ΠΈΠΎΠ½ΠΎΠ² Π½Π° ΠΎΡΠ°ΠΆΠ΄Π°Π΅ΠΌΡΡ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡ. Π€ΠΎΡΠΌΡΠ»Π° Π΄Π»Ρ ΡΠ°ΡΡΠ΅ΡΠ° Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΉΒ Π² ΠΎΡΠ°ΠΆΠ΄Π°Π΅ΠΌΠΎΠΌ ΠΏΠΎΠΊΡΡΡΠΈΠΈ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½Π°Ρ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΌΠΎΠ΄Π΅Π»ΠΈ Π½Π΅Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠΌΠΎΡΠΏΡΡΠ³ΠΎΠ³ΠΎ ΠΏΠΈΠΊΠ° ΠΈΠΎΠ½Π° Ρ ΡΡΠ΅ΡΠΎΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² Π°ΡΠΎΠΌΠ½ΠΎΠ³ΠΎΒ ΡΠ°ΡΠΏΡΠ»Π΅Π½ΠΈΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»Π°ΡΡ Π΄Π»Ρ ΡΠ°ΡΡΠ΅ΡΠ° Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΉ Π² ΠΏΠΎΠΊΡΡΡΠΈΡΡ
TiN ΠΈ CrN, ΠΎΡΠ°ΠΆΠ΄Π°Π΅ΠΌΡΡ
ΠΈΠ· ΠΏΠΎΡΠΎΠΊΠΎΠ² ΠΈΠΎΠ½ΠΎΠ² Ti+ ΠΈ Cr+,Β ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΠ΅Π»ΠΈΡΠΈΠ½Π° Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΉ Π΄Π»Ρ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Π½ΡΡ
ΠΏΠΎΠΊΡΡΡΠΈΠΉ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ ΠΌΠΎΠ΄ΡΠ»Π΅ΠΌ ΡΠΏΡΡΠ³ΠΎΡΡΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°Β ΠΏΠΎΠΊΡΡΡΠΈΡ. ΠΠ°ΠΊΡΠΈΠΌΡΠΌ ΠΊΡΠΈΠ²ΠΎΠΉ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΉ ΡΠΌΠ΅Π½ΡΡΠ°Π΅ΡΡΡ ΠΈ ΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ Π² ΠΎΠ±Π»Π°ΡΡΡ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΡ
ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΠΎΠ² Ρ ΡΠΎΡΡΠΎΠΌ ΡΠ³Π»Π°Β ΠΏΠ°Π΄Π΅Π½ΠΈΡ. Π’Π°ΠΊΠΎΠ΅ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠΌ ΡΠ°ΡΠΏΡΠ»Π΅Π½ΠΈΡ ΠΊΠ²Π°Π·ΠΈΡΡΠ°Π±ΠΈΠ»ΡΠ½ΡΡ
ΠΌΠ΅ΠΆΠ΄ΠΎΡΠ·Π΅Π»ΡΠ½ΡΡ
Π΄Π΅ΡΠ΅ΠΊΡΠΎΠ², ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΠΈΡ
Β ΡΡΠΎΠ²Π΅Π½Ρ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠΉ Π² ΠΎΡΠ°ΠΆΠ΄Π°Π΅ΠΌΠΎΠΌ ΠΏΠΎΠΊΡΡΡΠΈΠΈ. ΠΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π° ΡΠΎΡΠΌΡΠ»Π° Π΄Π»Ρ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΠΎΠΊΡΡΡΠΈΡ, ΡΡΠΈΡΡΠ²Π°ΡΡΠ°ΡΒ ΡΠ°ΡΠΏΡΠ»Π΅Π½ΠΈΠ΅ Π°ΡΠΎΠΌΠΎΠ² ΠΏΠΎΠΊΡΡΡΠΈΡ ΠΏΡΠΈ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π΅ ΡΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ³Π»Π΅ ΠΏΠ°Π΄Π΅Π½ΠΈΡ ΠΈΠΎΠ½ΠΎΠ². ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠ°ΡΠΏΡΠ»Π΅Π½ΠΈΠ΅Β ΡΠ΅Π·ΠΊΠΎ ΡΠ½ΠΈΠΆΠ°Π΅Ρ ΡΠΊΠΎΡΠΎΡΡΡ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΠΎΠΊΡΡΡΠΈΠΉ ΠΈ Π΄Π΅Π»Π°Π΅Ρ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠΌ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΡΡΡΠΈΠΉ TiN ΠΈ CrN Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠ³ΠΎΒ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π° ΠΏΡΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»Π°Ρ
Π½Π° ΠΏΠΎΠ΄Π»ΠΎΠΆΠΊΠ΅, ΠΏΡΠ΅Π²ΡΡΠ°ΡΡΠΈΡ
1,7 ΠΊΠ ΠΈ 0,7 ΠΊΠ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, ΠΈ ΠΏΡΠΈ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠΌ ΠΏΠ°Π΄Π΅Π½ΠΈΠΈΒ ΠΈΠΎΠ½ΠΎΠ². Π Π°ΡΠΏΡΠ»Π΅Π½ΠΈΠ΅ ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° Π²Π½ΡΡΡΠ΅Π½Π½Π΅Π΅ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΠ΅ ΠΈ ΡΠΊΠΎΡΠΎΡΡΡ ΡΠΎΡΡΠ° ΠΏΠΎΠΊΡΡΡΠΈΡ ΠΏΡΠΈ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΠΈΒ ΠΈΠΎΠ½ΠΎΠ² ΠΏΠΎΠ΄ Π½Π°ΠΊΠ»ΠΎΠ½Π½ΡΠΌΠΈ ΡΠ³Π»Π°ΠΌΠΈ ΠΏΠ°Π΄Π΅Π½ΠΈΡ Ξ± = 45Β°...70Β° . Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°ΡΡΠ΅ΡΠΎΠ² ΡΡΠ°Π²Π½ΠΈΠ²Π°ΡΡΡΡ Ρ ΠΈΠΌΠ΅ΡΡΠΈΠΌΠΈΡΡΒ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ
Decoration of nanovesicles with pH (low) insertion peptide (pHLIP) for targeted delivery
Acidity at surface of cancer cells is a hallmark of tumor microenvironments, which does not depend on tumor perfusion, thus it may serve as a general biomarker for targeting tumor cells. We used the pH (low) insertion peptide (pHLIP) for decoration of liposomes and niosomes. pHLIP senses pH at the surface of cancer cells and inserts into the membrane of targeted cells, and brings nanomaterial to close proximity of cellular membrane. DMPC liposomes and Tween 20 or Span 20 niosomes with and without pHLIP in their coating were fully characterized in order to obtain fundamental understanding on nanocarrier features and facilitate the rational design of acidity sensitive nanovectors. The samples stability over time and in presence of serum was demonstrated. The size, ΞΆ-potential, and morphology of nanovectors, as well as their ability to entrap a hydrophilic probe and modulate its release were investigated. pHLIP decorated vesicles could be useful to obtain a prolonged (modified) release of biological active substances for targeting tumors and other acidic diseased tissues
The place of intravenous immunoglobulin in rheumatic diseases
Therapy with intravenous human immunoglobulin (IVIG) was and continues to remain essential for a number of diseases. At the same time the evidence base for IVIG use is extremely small in rheumatology. Clinical experience shows that IVIG is effective in treating thrombocytopenic purpura, GuillainβBarre syndrome, and chronic inflammatory demyelinating polyneuropathy, which develop in the presence of rheumatic diseases, such as systemic lupus erythematosus, inflammatory myopathies, and antineutrophil cytoplasmic antibody-associated vasculitides. The review considers indications for the use of IVIG, its dosage regimen, benefits, and adverse reactions and analyzes the Russian and foreign literature on this issue
BRST approach to Lagrangian formulation for mixed-symmetry fermionic higher-spin fields
We construct a Lagrangian description of irreducible half-integer higher-spin
representations of the Poincare group with the corresponding Young tableaux
having two rows, on a basis of the BRST approach. Starting with a description
of fermionic higher-spin fields in a flat space of any dimension in terms of an
auxiliary Fock space, we realize a conversion of the initial operator
constraint system (constructed with respect to the relations extracting
irreducible Poincare-group representations) into a first-class constraint
system. For this purpose, we find auxiliary representations of the constraint
subsuperalgebra containing the subsystem of second-class constraints in terms
of Verma modules. We propose a universal procedure of constructing
gauge-invariant Lagrangians with reducible gauge symmetries describing the
dynamics of both massless and massive fermionic fields of any spin. No
off-shell constraints for the fields and gauge parameters are used from the
very beginning. It is shown that the space of BRST cohomologies with a
vanishing ghost number is determined only by the constraints corresponding to
an irreducible Poincare-group representation. To illustrate the general
construction, we obtain a Lagrangian description of fermionic fields with
generalized spin (3/2,1/2) and (3/2,3/2) on a flat background containing the
complete set of auxiliary fields and gauge symmetries.Comment: 41 pages, no figures, corrected typos, updated introduction, sections
5, 7.1, 7.2 with examples, conclusion with all basic results unchanged,
corrected formulae (3.27), (7.138), (7.140), added dimensional reduction part
with formulae (5.34)-(5.48), (7.8)-(7.10), (7.131)-(7.136), (7.143)-(7.164),
added Refs. 52, 53, 54, examples for massive fields developed by 2 way
LABOR PRODUCTIVITY AS A PRODUCTION EFFICIENCY FACTOR
El objetivo de esta investigacioΜn es estudiar el factor de eficiencia y la productividad laboral. En gran medida, el nivel de productividad laboral crecioΜ debido a la intensificacioΜn de la produccioΜn. Al mismo tiempo, seguΜn Rosstat, en agricultura, silvicultura y pesca solo hay un 8% de empleos altamente eficientes. Por lo tanto, el factor de intensificacioΜn de la produccioΜn se utiliza de manera insignificante. Es obvio que hay una necesidad de un componente innovador del crecimiento de la productividad laboral, por un lado, y la creacioΜn de nuevos empleos en las zonas rurales para los recursos laborales liberados, por otro lado. AquiΜ es necesario determinar los principales factores que afectan la productividad en las condiciones modernas, y justificar las propuestas para mejorarla.Of the goal of this investigation is to study the efficiency factor and labor productivity. To a large extent, the level of labor productivity grew due to the intensification of production. At the same time, according to Rosstat, in agriculture, forestry and fisheries there are only 8% of high-efficient jobs. Thus, the factor of production intensification is used insignificantly. It is obvious that there is a need for an innovative component of labor productivity growth on the one hand, and the creation of new jobs in rural areas for the released labor resources, on the other hand. Here it is necessary to determine the main factors affecting productivity in modern conditions, and to justify proposals to improve it.O objetivo desta investigacΜ§aΜo eΜ estudar o fator de eficieΜncia e a produtividade do trabalho. Em grande medida, o niΜvel de produtividade do trabalho aumentou devido aΜ intensificacΜ§aΜo da producΜ§aΜo. Ao mesmo tempo, segundo Rosstat, na agricultura, silvicultura e pesca, existem apenas 8% dos empregos de alta eficieΜncia. Assim, o fator de intensificacΜ§aΜo da producΜ§aΜo eΜ usado de forma insignificante. EΜ oΜbvio que eΜ necessaΜrio um componente inovador do crescimento da produtividade do trabalho, por um lado, e a criacΜ§aΜo de novos empregos nas aΜreas rurais para os recursos liberados, por outro. Aqui eΜ necessaΜrio determinar os principais fatores que afetam a produtividade nas condicΜ§oΜes modernas e justificar propostas para melhoraΜ- la
Closed geodesics in Alexandrov spaces of curvature bounded from above
In this paper, we show a local energy convexity of maps into
spaces. This energy convexity allows us to extend Colding and
Minicozzi's width-sweepout construction to produce closed geodesics in any
closed Alexandrov space of curvature bounded from above, which also provides a
generalized version of the Birkhoff-Lyusternik theorem on the existence of
non-trivial closed geodesics in the Alexandrov setting.Comment: Final version, 22 pages, 2 figures, to appear in the Journal of
Geometric Analysi
Π‘ΠΈΡΡΠ΅ΠΌΠ° Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° Π² Π½ΠΎΡΠΌΠ΅ ΠΈ ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ (ΠΎΠ±Π·ΠΎΡ)
The review dwells on the problem of hemostatic disorders in patients undergoing liver transplantation and their correction in the perioperative period. The physiology of the hemostatic system, disorders of the blood coagulation system in patients at various stages of liver transplantation, correction of hemostatic disorders during and after orthotopic liver transplantation are discussed. Liver transplantation is performed in patients with liver diseases in the terminal stage of liver failure. At the same time, changes in the hemostatic system of these patients pose a significant risk of developing bleeding and/or thrombosis during and after liver transplantation. The hypothesis is suggested that the personalized correction of hemostasis disorder in liver transplantation should be based on considerating the nosological forms of the liver damage, mechanisms of development of recipientβs hemostatic disorders, and the stage of the surgery.ΠΠ±Π·ΠΎΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΈ ΠΈΡ
ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°ΡΡΠΈΡ
ΡΡ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ. ΠΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ: ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π°; Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ²Π΅ΡΡΡΠ²Π°ΡΡΠ΅ΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ; ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° Π²ΠΎ Π²ΡΠ΅ΠΌΡ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΡΡΠΎΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ. Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π²ΡΠΏΠΎΠ»Π½ΡΠ΅ΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π² ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ. ΠΡΠΈ ΡΡΠΎΠΌ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΡΡΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ, ΠΊΠ°ΠΊ ΠΊΡΠΎΠ²ΠΎΡΠ΅ΡΠ΅Π½ΠΈΠΉ, ΡΠ°ΠΊ ΠΈ ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ² Π²ΠΎ Π²ΡΠ΅ΠΌΡ ΠΈ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ. ΠΠΎΡΡΠ΅ΠΊΡΠΈΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΠΏΡΠΈ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ Π΄ΠΎΠ»ΠΆΠ½Π° ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΡΡ Ρ ΡΡΠ΅ΡΠΎΠΌ Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΡ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ°Π·Π²ΠΈΡΠΈΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Π³Π΅ΠΌΠΎΡΡΠ°Π·Π° ΡΠ΅ΡΠΈΠΏΠΈΠ΅Π½ΡΠ° ΠΈ ΡΡΠ°ΠΏΠ° ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ
MARKERS OF INFLAMMATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND CARDIOVASCULAR PATHOLOGY
Objective: to estimate the levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-Ξ±), and soluble TNF-Ξ± receptor type 1 (sTNF-R1) in patients with antiphospholipid syndrome (APS) and their association with cardiovascular pathology. Subjects and methods. Ninety-six patients, including 52 with primary APS and 44 with systemic lupus erythematosus and APS, were examined. A control group comprised 29 individuals without the signs of autoimmune disease. The levels of hsCRP, IL-6, TNF-Ξ±, sTNF-R1, antiphospholipid antibodies, and plasma lipids were studied; ultrasonography measuring the carotid intima-media complex (IMC), electrocardiography (ECG), echocardiography, and Holter ECG monitoring were made. Results. The concentrations of hsCRP, IL-6, TNF-Ξ±, and sTNF-R1 were significantly higher in the patient groups than in the controls (p < 0.05). Elevated sTNF-R1 concentrations were more common in angina pectoris than in its absence (OR = 2.13; 95% CI [1.51; 2.99]; p < 0.001). In patients with damage to the valvular apparatus, IL-6, TNF-Ξ±, and sTNF-R1 concentrations were significantly higher than those in patients without the defects (p = 0.02, 0.02, and 0.01, respectively). The levels of TNF-Ξ± and sTNF-R1 were significantly higher in hypertensive patients than those in non-hypertensives (p = 0.002 and p < 0.001; respectively). The blood concentration of TNF-Ξ± was significantly higher in patients having the risk factors and subclinical signs of atherosclerosis that that in those without the signs and risk factors of atherosclerosis (p < 0.05). Analysis showed a direct correlation between the levels of TNF-Ξ±, hsCRP, IL-6, and sTNF-R1 and an inverse correlation of those of IL-6 and TNF-Ξ± with the duration of posttrombosis (p < 0.05). A correlation was found between the concentrations of TNF-Ξ± and sTNF-R1, and IMC of the great arteries, as well as the cumulative coronary risk (p < 0.05). Conclusion. In patients with APS, the levels of all the test markers were significantly higher than those in the controls. An association was revealed between the values of TNF-Ξ± and sTNF-R1 and the risk factors and subclinical signs of atherosclerosis
ΠΠ΅ΡΡΠΎ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½Π° ΠΏΡΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
Therapy with intravenous human immunoglobulin (IVIG) was and continues to remain essential for a number of diseases. At the same time the evidence base for IVIG use is extremely small in rheumatology. Clinical experience shows that IVIG is effective in treating thrombocytopenic purpura, GuillainβBarre syndrome, and chronic inflammatory demyelinating polyneuropathy, which develop in the presence of rheumatic diseases, such as systemic lupus erythematosus, inflammatory myopathies, and antineutrophil cytoplasmic antibody-associated vasculitides. The review considers indications for the use of IVIG, its dosage regimen, benefits, and adverse reactions and analyzes the Russian and foreign literature on this issue.Π’Π΅ΡΠ°ΠΏΠΈΡ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΡΠΌ ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΈΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΎΠΌ (ΠΠΠΠ) Π±ΡΠ»Π° ΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°Π΅Ρ ΠΎΡΡΠ°Π²Π°ΡΡΡΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΠΏΡΠΈ ΡΡΠ΄Π΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠ½Π°Ρ Π±Π°Π·Π° ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠΠΠ Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΊΡΠ°ΠΉΠ½Π΅ ΠΌΠ°Π»Π°. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠΏΡΡ ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ, ΡΡΠΎ ΠΠΠΠ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π΅Π½ ΠΏΡΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠΏΠ΅Π½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΡΠΏΡΡΠ΅, ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ ΠΠΈΠΉΠ΅Π½Π°βΠΠ°ΡΡΠ΅ ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·ΠΈΡΡΡΡΠ΅ΠΉ ΠΏΠΎΠ»ΠΈΠ½Π΅Π²ΡΠΎΠΏΠ°ΡΠΈΠΈ, ΡΠ°Π·Π²ΠΈΠ²ΡΠΈΡ
ΡΡ Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, ΡΠ°ΠΊΠΈΡ
ΠΊΠ°ΠΊ ΡΠΈΡΡΠ΅ΠΌΠ½Π°Ρ ΠΊΡΠ°ΡΠ½Π°Ρ Π²ΠΎΠ»ΡΠ°Π½ΠΊΠ°, Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈ ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Ρ Π°Π½ΡΠΈΠ½Π΅ΠΉΡΡΠΎΡΠΈΠ»ΡΠ½ΡΠΌΠΈ ΡΠΈΡΠΎΠΏΠ»Π°Π·ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌΠΈ Π²Π°ΡΠΊΡΠ»ΠΈΡΡ. Π ΠΎΠ±Π·ΠΎΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡ ΠΊ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠΠΠ, ΡΠ΅ΠΆΠΈΠΌ Π΄ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΠΈ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ, ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΈ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎ Π΄Π°Π½Π½ΠΎΠΌΡ Π²ΠΎΠΏΡΠΎΡ
- β¦